ASSOCIATION BETWEEN ANGIOTENSIN-CONVERTING ENZYME GENE POLYMORPHISM AND LEFT VENTRICULAR REMODELING AFTER MYOCARDIAL INFARCTION
血管紧张素转换酶基因多态性与心肌梗死后左心室重构的相关性
基本信息
- 批准号:07670821
- 负责人:
- 金额:$ 1.41万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:1995
- 资助国家:日本
- 起止时间:1995 至 1997
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Angiotensin-converting enzyme (ACE) gene insertion / deletion (I/D) polymorphism has been demonstrated to be associated with serum and cardiac ACE activity. To evaluate the association of the ACE gene I/D polymorphism with left ventricular remodeling and in-hospital mortality, we studied 290 consecutive patients with a first myocardial infarction who were admitted to our cardiovascular center.There were 82 patients who received echocardiography 2 weeks and 1 year after onset of myocardial infaction. Left ventricular remodeling was defined as the increase in left ventricular end-diastolic volume index * 20% at the recording of echocardiogram 1 year after onset compared to that of 2 weeks after onset. There were 11 patients with the DD genotype, 38 patients with the ID genotype, and 33 patients with the II genotype. Left ventricular remodeling was found in 4 patients (36%) of the DD genotype, 9 patients (24%) of the ID genotype, and 6 patients (18%) of the II genotype. Biological gradien … More t was observed among these 3 groups, but did not reach statistical significance (p=0.1591). Logistic regression analysis was used to evaluate the association of the ACE gene genotype (DD v.s.ID/II) with left ventricular remodeling. After adjustment for age, site of myocardial infarction, reperfusion therapy during acute phase, ACE inhibitor use, history of hypertension, and ejection fraction 2 weeks after onset, the DD genotype had a tendency to be associated with left ventricular remodeling (odds ratio=2.486, p=0.1722). Our sample size might be too small to detect a 15% difference in the incidence of left ventricular remodeling between the DD and the ID/II genotypes.On the other hand, in-hospital mortality was compared between the DD genotype and the ID/II genotypes in 290 consecutive patients using the logistic regression analysis adjusted for age, sex, site of myocardial infarction, Killip functional class, reperfusion therapy during acute phase, ACE inhibitor use, and beta-blocker use. There were 45 patients with the DD genotype, 128 patients with the ID genotype, and 117 patients with the II genotype. Twenty-eight patients died during hospitalization (1 with the DD,18 with the ID,and 9 with the II genotype). The DD genotype was significantly associated with lower in-hospital mortality (p=0.0227) after adjustment for the clinical variables. Our results clinically supported preconditioning effect of angiotensin II observed in experimental studies. Less
血管紧张素转换酶(ACE)基因插入/缺失(I/D)多态性已被证明与血清和心脏ACE活性相关。为了评价ACE基因I/D多态性与左心室重构和住院死亡率的关系,我们研究了290例首次心肌梗死的患者,其中82例患者在心肌梗死发生后2周和1年接受了超声心动图检查。左心室重构定义为与发病后2周相比,发病后1年超声心动图记录的左心室舒张末期容积指数增加 * 20%。有11例患者为DD基因型,38例患者为ID基因型,33例患者为II基因型。DD基因型4例(36%)、ID基因型9例(24%)、II基因型6例(18%)出现左室重构。生物梯度 ...更多信息 在这3组中观察到t,但未达到统计学显著性(p=0.1591)。采用Logistic回归分析评价ACE基因型(DD vs. ID/II)与左室重构的关系。在校正年龄、心肌梗死部位、急性期再灌注治疗、ACE抑制剂使用、高血压病史和发病后2周射血分数后,DD基因型倾向于与左心室重构相关(比值比=2.486,p=0.1722)。我们的样本量可能太小,无法检测到DD和ID/II基因型之间左心室重构发生率的15%差异。另一方面,在290例连续患者中,使用logistic回归分析比较DD基因型和ID/II基因型之间的住院死亡率,该分析调整了年龄、性别、心肌梗死部位、Killip功能分级、急性期再灌注治疗、ACE抑制剂使用和β受体阻滞剂使用。其中DD型45例,ID型128例,II型117例。28例患者在住院期间死亡(1例DD,18例ID,9例II基因型)。在调整临床变量后,DD基因型与较低的住院死亡率显著相关(p=0.0227)。我们的研究结果在临床上支持血管紧张素II的预适应作用在实验研究中观察到。少
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
IWASAKA Toshiji其他文献
IWASAKA Toshiji的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('IWASAKA Toshiji', 18)}}的其他基金
The role of oxidative stress and antioxidant dilemma in ischemic heart disease
氧化应激和抗氧化困境在缺血性心脏病中的作用
- 批准号:
20590847 - 财政年份:2008
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Angiogeniseis and angiotensin II
血管生成和血管紧张素 II
- 批准号:
13670761 - 财政年份:2001
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
INFLUENCE OF BRAIN NATRIURETIC PEPTIDE DURING ACUTE PHASE ON LEFT VENTRICULAR REMODELING 1 YEAR AFTER MYOCARDIAL INFARCTION
急性期脑钠肽对心肌梗死后1年左心室重构的影响
- 批准号:
10670684 - 财政年份:1998
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Structure and function study of angiotensin converting enzyme 2 (ACE2) activating peptides from food proteins
食品蛋白中血管紧张素转换酶 2 (ACE2) 激活肽的结构和功能研究
- 批准号:
RGPIN-2018-04680 - 财政年份:2022
- 资助金额:
$ 1.41万 - 项目类别:
Discovery Grants Program - Individual
Domain-specific inhibition of angiotensin-converting enzyme as a therapeutic strategy for opioid use disorders
血管紧张素转换酶的域特异性抑制作为阿片类药物使用障碍的治疗策略
- 批准号:
10512191 - 财政年份:2022
- 资助金额:
$ 1.41万 - 项目类别:
Role of gut commensal Coprococcus comes in angiotensin-converting enzyme inhibitor resistant hypertension
肠道共生粪球菌在血管紧张素转换酶抑制剂抵抗性高血压中的作用
- 批准号:
10509954 - 财政年份:2022
- 资助金额:
$ 1.41万 - 项目类别:
Role of gut commensal Coprococcus comes in angiotensin-converting enzyme inhibitor resistant hypertension
肠道共生粪球菌在血管紧张素转换酶抑制剂抵抗性高血压中的作用
- 批准号:
10676297 - 财政年份:2022
- 资助金额:
$ 1.41万 - 项目类别:
Functional analysis of angiotensin-converting enzyme 2 in the brain and development of novel therapeutic agents for depression
脑血管紧张素转换酶2的功能分析及新型抑郁症治疗药物的开发
- 批准号:
22K06866 - 财政年份:2022
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
COVID-19 Variant Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
COVID-19 变异补充剂 - 使用血管紧张素转换酶 2 (ACE2) 对抗 COVID-19 的分子和细胞疗法
- 批准号:
443128 - 财政年份:2021
- 资助金额:
$ 1.41万 - 项目类别:
Operating Grants
Determine how the interaction between SARS-CoV-2 spike protein and angiotensin-converting enzyme 2 (ACE2) affect viral spread and the severity of COVID-19 outcomes.
确定 SARS-CoV-2 刺突蛋白和血管紧张素转换酶 2 (ACE2) 之间的相互作用如何影响病毒传播和 COVID-19 结果的严重程度。
- 批准号:
449017 - 财政年份:2021
- 资助金额:
$ 1.41万 - 项目类别:
Operating Grants
Development and Evaluation of Radiotracers for PET Imaging Angiotensin-Converting Enzyme 2 (ACE2)
PET 成像血管紧张素转换酶 2 (ACE2) 放射性示踪剂的开发和评估
- 批准号:
10286888 - 财政年份:2021
- 资助金额:
$ 1.41万 - 项目类别:
Development and Evaluation of Radiotracers for PET Imaging Angiotensin-Converting Enzyme 2 (ACE2)
PET 成像血管紧张素转换酶 2 (ACE2) 放射性示踪剂的开发和评估
- 批准号:
10612920 - 财政年份:2021
- 资助金额:
$ 1.41万 - 项目类别:
Interaction between genetic, lifestyle and environmental factors determining circulating angiotensin-converting enzyme 2 protein expression: implications for the severity of COVID-19 infection
遗传、生活方式和环境因素之间的相互作用决定循环血管紧张素转换酶 2 蛋白表达:对 COVID-19 感染严重程度的影响
- 批准号:
10228516 - 财政年份:2021
- 资助金额:
$ 1.41万 - 项目类别: